PortfoliosLab logoPortfoliosLab logo
AGIO vs. NVO
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

AGIO vs. NVO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Agios Pharmaceuticals, Inc. (AGIO) and Novo Nordisk A/S (NVO). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, AGIO achieves a 48.97% return, which is significantly higher than NVO's 0.24% return. Over the past 10 years, AGIO has underperformed NVO with an annualized return of -0.29%, while NVO has yielded a comparatively higher 8.21% annualized return.


AGIO

1D
-1.65%
1M
37.64%
6M
43.19%
YTD
48.97%
1Y
3.84%
3Y*
14.21%
5Y*
-6.22%
10Y*
-0.29%

NVO

1D
-0.40%
1M
12.31%
6M
-14.80%
YTD
0.24%
1Y
-25.17%
3Y*
-12.72%
5Y*
4.73%
10Y*
8.21%
*Multi-year figures are annualized to reflect compound growth (CAGR)

AGIO vs. NVO - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
AGIO
Agios Pharmaceuticals, Inc.
48.97%-17.16%47.55%-20.69%-14.57%-24.14%-9.26%3.56%-19.35%37.00%
NVO
Novo Nordisk A/S
0.24%-39.22%-15.93%54.84%22.66%63.52%23.33%28.70%-12.98%52.92%

Correlation

The correlation between AGIO and NVO is 0.24, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.24

Correlation (3Y)
Calculated over the trailing 3-year period

0.21

Correlation (5Y)
Calculated over the trailing 5-year period

0.20

Correlation (10Y)
Calculated over the trailing 10-year period

0.20

Correlation (All Time)
Calculated using the full available price history since Jul 24, 2013

0.22

Fundamentals

Market Cap

AGIO:

$2.41B

NVO:

$218.99B

EPS

AGIO:

-$7.23

NVO:

DKK 27.42

PS Ratio

AGIO:

35.87

NVO:

4.39

PB Ratio

AGIO:

2.15

NVO:

7.08

Total Revenue (TTM)

AGIO:

$66.05M

NVO:

DKK 327.80B

Gross Profit (TTM)

AGIO:

$59.47M

NVO:

DKK 268.30B

EBITDA (TTM)

AGIO:

-$443.16M

NVO:

DKK 181.54B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

AGIO vs. NVO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AGIO
AGIO Risk / Return Rank: 5050
Overall Rank
AGIO Sharpe Ratio Rank: 4747
Sharpe Ratio Rank
AGIO Sortino Ratio Rank: 5050
Sortino Ratio Rank
AGIO Omega Ratio Rank: 6060
Omega Ratio Rank
AGIO Calmar Ratio Rank: 4747
Calmar Ratio Rank
AGIO Martin Ratio Rank: 4747
Martin Ratio Rank

NVO
NVO Risk / Return Rank: 2525
Overall Rank
NVO Sharpe Ratio Rank: 2323
Sharpe Ratio Rank
NVO Sortino Ratio Rank: 2525
Sortino Ratio Rank
NVO Omega Ratio Rank: 2323
Omega Ratio Rank
NVO Calmar Ratio Rank: 2727
Calmar Ratio Rank
NVO Martin Ratio Rank: 2929
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

AGIO vs. NVO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Agios Pharmaceuticals, Inc. (AGIO) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


AGIONVODifference
Sharpe ratioReturn per unit of total volatility

+0.54

Sortino ratioReturn per unit of downside risk

+1.03

Omega ratioGain probability vs. loss probability

1.14

0.94

+0.19

Calmar ratioReturn relative to maximum drawdown

0.08

-0.51

+0.59

Martin ratioReturn relative to average drawdown

0.13

-0.80

+0.93

AGIO vs. NVO - Sharpe Ratio Comparison

The current AGIO Sharpe Ratio is 0.05, which is higher than the NVO Sharpe Ratio of -0.49. The chart below compares the historical Sharpe Ratios of AGIO and NVO, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

AGIO vs. NVO - Drawdown Comparison

The maximum AGIO drawdown since its inception was -87.36%, which is greater than NVO's maximum drawdown of -74.70%. Use the drawdown chart below to compare losses from any high point for AGIO and NVO.


Loading charts...

Drawdown Indicators


AGIONVODifference

Max Drawdown

Largest peak-to-trough decline

-87.36%

-74.70%

-12.66%

Max Drawdown (1Y)

Largest decline over 1 year

-50.89%

-49.17%

-1.72%

Max Drawdown (3Y)

Largest decline over 3 years

-63.76%

-74.70%

+10.94%

Max Drawdown (5Y)

Largest decline over 5 years

-69.93%

-74.70%

+4.77%

Max Drawdown (10Y)

Largest decline over 10 years

-82.86%

-74.70%

-8.16%

Current Drawdown

Current decline from peak

-69.97%

-64.19%

-5.78%

Average Drawdown

Average peak-to-trough decline

-58.94%

-17.87%

-41.07%

Ulcer Index

Depth and duration of drawdowns from previous peaks

29.17%

31.54%

-2.37%

Volatility

AGIO vs. NVO - Volatility Comparison

Agios Pharmaceuticals, Inc. (AGIO) has a higher volatility of 19.69% compared to Novo Nordisk A/S (NVO) at 8.73%. This indicates that AGIO's price experiences larger fluctuations and is considered to be riskier than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


AGIONVODifference

Volatility (1M)

Calculated over the trailing 1-month period

19.69%

8.73%

+10.96%

Volatility (6M)

Calculated over the trailing 6-month period

44.30%

37.44%

+6.86%

Volatility (1Y)

Calculated over the trailing 1-year period

76.86%

51.74%

+25.12%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

59.46%

38.53%

+20.93%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

56.91%

32.60%

+24.31%

Dividends

AGIO vs. NVO - Dividend Comparison

AGIO has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 3.66%.


PositionTTM20252024202320222021202020192018201720162015
AGIO
Agios Pharmaceuticals, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
NVO
Novo Nordisk A/S
3.66%3.31%1.68%1.00%1.20%1.35%1.87%2.14%1.45%1.52%2.87%0.92%

Financials

AGIO vs. NVO - Financials Comparison

This section allows you to compare key financial metrics between Agios Pharmaceuticals, Inc. and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00B40.00B60.00B80.00B100.00BJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober2026
20.75M
96.82B
(AGIO) Total Revenue
(NVO) Total Revenue
Please note, different currencies. AGIO values in USD, NVO values in DKK

Frequently Asked Questions


AGIO and NVO have a correlation of 0.24, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

AGIO has higher volatility (19.69%) compared to NVO (8.73%). In terms of maximum drawdown, AGIO dropped -87.36% vs NVO's -74.70%.

AGIO currently has the higher Sharpe Ratio (0.05 vs -0.49), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for AGIO and NVO

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer